← Eichor
Study identifier: NCT04208828 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy

Condition: Gastrointestinal Motility Disorder · Gastroparesis · Neuropathy  ·  Sponsor: University of Louisville

PhaseN/A
Planned participants400
Who can joinAll sexes, 12 Years to 90 Years
Healthy volunteersNo

About this study

Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions/ Some of these patients have serologic and/or endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.

This description comes directly from the study's public registry record.

Talk to the study team

Thomas L Abell, MD  ·  (502)852-6991  ·  thomas.abell@louisville.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of LouisvilleLouisville, Kentucky, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04208828